Multitarget stool DNA test shows promise for early colorectal cancer detection

A recent prospective cross-sectional study in Thailand demonstrates that multitarget stool DNA testing is highly sensitive and specific for detecting colorectal cancer (CRC) among Thai individuals.

Sparsentan Bests Irbesartan for Rare, Progressive Kidney Disease

LONG BEACH, Calif. — Sparsentan (Filspari) led to more complete and partial remissions of focal segmental glomerulosclerosis (FSGS) compared with irbesartan (Avapro), the phase III

May 18, 2024

Ketogenic diet can be a powerful aid in treating mental illness

For people living with serious mental illness like schizophrenia or bipolar disorder, standard treatment with antipsychotic medications can be a double-edged sword.

April 1, 2024

MaxCyte® acquires SeQure Dx to broaden cell engineering offerings with on-target and off-target editing assessments

MaxCyte, Inc., a leading, cell-engineering focused company providing solutions to advance the discovery, development and commercialization of next-generation cell therapeutics announced today the acquisition of

February 6, 2025

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.